title: Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study.
abstract: BACKGROUND
  Neuroprotective effects of lithium (Li) have been well documented in tissue cultures and animal models, whereas human data continue to be limited. Previous studies investigating the association between Li treatment and brain N-acetylaspartate (NAA), a putative neuronal marker, showed mixed results because of methodological heterogeneity.
  
  
  METHODS
  To investigate the effects of Li on prefrontal cortex NAA levels, we compared patients with bipolar disorder from specialized Li clinics in Berlin and Halifax with at least 2 years of ongoing Li treatment (Li group), patients with lifetime Li exposure of less than 3 months more than 2 years ago (non-Li group) and healthy controls. Participants in both patient groups had at least 10 years of illness and 5 episodes. We measured left prefrontal NAA levels using 1.5-T magnetic resonance spectroscopy.
  
  
  RESULTS
  We enrolled 27 participants in the Li, 16 in the non-Li and 21 in the healthy control groups. The non-Li group had lower prefrontal NAA levels than the Li group (t41 = -3.44, corrected p < 0.01) or control participants (t35 = -2.91, corrected p < 0.05), who did not differ from the Li group (t46 = -0.14, p = 0.89). The same pattern of prefrontal NAA differences was replicated in both sites. In addition, there was a negative correlation between prefrontal NAA and duration of illness in the non-Li group (r = -0.60, p = 0.019) but not in the Li group (r = 0.07, p = 0.74).
  
  
  CONCLUSIONS
  Study limitations include the crosssectional design and exposure to other medications.
  
  
  CONCLUSIONS
  Whereas patients with bipolar disorder, substantial illness burden and limited lifetime Li exposure had significantly lower prefrontal NAA levels than controls, Li-treated patients with similar illness burden showed prefrontal NAA levels comparable to those of healthy controls. These findings provide indirect support for neuroprotective effects of Li and for negative effects of illness burden on prefrontal NAA levels in patients with bipolar disorder.
authors.affiliation: Department of Psychiatry, Dalhousie University, Halifax, NS. tomas.hajek@dal.ca
authors.forename: Tomas
authors.initials: T
authors.lastname: Hajek
authors.forename: Michael
authors.initials: M
authors.lastname: Bauer
authors.forename: Andrea
authors.initials: A
authors.lastname: Pfennig
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Cullis
authors.forename: Jana
authors.initials: J
authors.lastname: Ploch
authors.forename: Claire
authors.initials: C
authors.lastname: O'Donovan
authors.forename: Georg
authors.initials: G
authors.lastname: Bohner
authors.forename: Randolf
authors.initials: R
authors.lastname: Klingebiel
authors.forename: L Trevor
authors.initials: LT
authors.lastname: Young
authors.forename: Glenda M
authors.initials: GM
authors.lastname: Macqueen
authors.forename: Martin
authors.initials: M
authors.lastname: Alda
mesh_terms: D000328:Adult; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000378:metabolism*; D017281:Cost of Illness; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D018020:Lithium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D011569:Psychiatric Status Rating Scales
chemical_list: D018020:Lithium Compounds; D018696:Neuroprotective Agents; D001224:Aspartic Acid; C000179:N-acetylaspartate